Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds
Haiyan Wang, Shasha Li, Qianyu Wang, Zhengshuo Jin, Wei Shao, Yan Gao, Lu Li, Kequan Lin, Lin Zhu, Huili Wang, Xuebin Liao, Dong Wang
Abstract
through inhibiting aurora kinase A (AURKA)-signal transducer and activator of transcription 3 (STAT3) signaling pathway, which promotes effective T cells infiltrating into tumor microenvironment and improves anti-programmed cell death 1 (PD-1) efficacy in preclinical models. Our study established a novel strategy to discover combination immunotherapy compounds and suggested the therapeutic potential of combining AKIs with ICB for the treatment of TNBC.
Topics & Concepts
ImmunotherapyHigh-throughput screeningDrug discoveryImmune systemSignature (topology)ThroughputComputational biologyBooster (rocketry)Phenotypic screeningPhenotypeMedicineBiologyComputer scienceImmunologyBioinformaticsGeneGeneticsAstronomyGeometryMathematicsWirelessPhysicsTelecommunicationsCancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmunotherapy and Immune Responses